For personal use only

ASX ANNOUNCEMENT
26 October 2026

Board Change: John Murray retires as PainChek non-executive director after 10 years service

PainChek Limited (ASX: PCK) advises that Non-Executive Director and former Chair, John Murray, has retired from the Board with immediate effect.

John joined the Board as Chair in September 2016, when PainChek was focused on research, development and preparing its technology for commercialisation. He served as Chair until May 2026, helping guide the Company's transition from an early-stage technology developer to an established commercial business with regulatory approved operations across Australia, New Zealand, the United Kingdom, USA and Canada.

The Board thanks John for his leadership, commitment and contribution over a decade. His support through the development, validation and commercialisation of PainChek's technology helped establish the foundations on which the Company is now building.

Supporting the next phase of growth

PainChek's focus is translating its technology, customer relationships and international market access into increased adoption, implemented licences and recurring revenue.

The Company's growth priorities are to progress commercial deployments and customer expansion in USA and Canada, accelerate implementation and adoption in the United Kingdom, and retain and expand its established customer base in Australia and New Zealand.

As the Company enters this next phase, the Board will ensure it meets the future with complementary skills and experience in international healthcare commercialisation, scaling technology businesses and disciplined commercial execution.

PainChek Chair Lil Bianchi said:

"John has played an important role in PainChek's development over the past decade. His leadership and commitment helped guide the Company from research and development through to commercialisation and international expansion. On behalf of the Board and the wider team, I thank him for his substantial contribution.

"PainChek now has an established commercial platform, with more than 21 million pain assessments completed and customers across multiple international markets. Our focus is on building on that foundation through stronger customer adoption, recurring revenue growth and disciplined execution..

"We wish John every success in his future endeavours."

John Murray commented:

"PainChek is well positioned for the next phase with new board and executive leadership and growing international markets. I have therefore decided this is the right time to step down. My period as non-executive director and Chair has seen The Company make the transition to commercialisation, securing an expanding customer base with strong rates of retention and satisfaction. I look forward to PainChek's on-going success."

Authorised for release by the Board of PainChek Limited.

ENDS

For more information

Natalie Climo
Company Secretary, PainChek
natalie.climo@boardroomlimited.com.au
02 8016 2875

Media enquiries

David Tasker
Managing Director, Chapter One Advisors
dtasker@chapteroneadvisors.com.au
+61 433 112 936

About PainChek

PainChek develops digital pain assessment and monitoring tools to support care for people who cannot reliably self-report pain. Its application combines AI-assisted facial analysis with a structured clinical assessment and the Numerical Rating Scale, supported by reporting and analytics.

www.painchek.com

For personal use only